Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GCC19CART |
| Synonyms | |
| Therapy Description |
GCC19CART is a chimeric antigen receptor (CAR) T-cell therapy comprising T-lymphocytes that target guanylate cyclase-C (GUY2C) and CD19, potentially resulting in antitumor activity (Cancer Res (2023) 83 (7_Supplement): 1130). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GCC19CART | GCC19-CART|GCC19 CART | CD19 Immune Cell Therapy 72 | GCC19CART is a chimeric antigen receptor (CAR) T-cell therapy comprising T-lymphocytes that target guanylate cyclase-C (GUY2C) and CD19, potentially resulting in antitumor activity (Cancer Res (2023) 83 (7_Supplement): 1130). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05319314 | Phase I | GCC19CART | GCC19CART for Patients With Metastatic Colorectal Cancer (CARAPIA-1) | Unknown status | USA | 0 |